Across 4 review studies, all reported beneficial effects of Lactobacillus acidophilus L-92 on allergic symptoms, with moderate effect sizes in 3 studies and a small effect in 1 study. The evidence derives entirely from reviews of human clinical trials, predominantly in populations with atopic dermatitis and allergic rhinitis. No dose, form, or duration data were consistently reported, limiting specificity.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. None of the included studies reported statistical significance, and all are reviews rather than primary trials, which reduces certainty.
Lactobacillus acidophilus L-92 has been reported to improve symptoms in patients with atopic dermatitis and allergic rhinitis in human studies.
Lactobacillus acidophilus L-92 has been reported to help prevent and manage gastrointestinal and systemic disorders.
A number of preclinical and clinical studies suggest that these biotics and metabolites have promising health effects...
Lactobacillus acidophilus L-92 has been reported to alleviate symptoms of pollen allergy, atopic dermatitis, and house dust mite allergy in human clinical studies.